A large amount of evidence from literature has manifested that tumor cells can effectively
avoid being recognized and killed by the immune system through immune checkpoint …

The success of immunotherapy in many disease entities is limited to a specific
subpopulation of patients. To overcome this problem, dual blockade treatments mainly …

Introduction Lymphocyte activation gene-3 (LAG-3) is a member of the immunoglobulin
superfamily. Engagement of LAG-3 by its ligands to trigger downstream signaling can inhibit …

The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs),
has brought new life to cancer treatment, and ICIs can effectively treat various tumors …

Background Lymphocyte-activating gene-3 (LAG-3) is a cell surface inhibitory receptor with
multiple biological activities over T cell activation and effector functions. LAG-3 is the third …

LAG-3 (Lymphocyte activation gene 3) protein is a checkpoint receptor that interacts with
LSEC-tin, Galectin-3 and FGL1. This interaction leads to reduced production of IL-2 and IFN …

Lymphocyte-activation gene 3 (LAG-3) is a coreceptor found on activated T-lymphocytes
activated B-lymphocytes and natural killer (NK) cells. It is closely related to CD4 where it …

Highlights•LAG-3 is a highly important next-generation immune checkpoint molecule.•Ninety-
seven clinical trials are evaluating at least 16 LAG-3-targeting molecules.•Here we identify …

Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and
programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …